Current partner codePEPTIDESDE
NCT03383393·Not applicable·OBSERVATIONAL

Pharmacologic Treatment of Myocardial Ischemia Detected by Intracoronary ECG

Status

Unknown

Phase

Not applicable

Enrollment

60

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

After PCI searching for target lesion ischemia with intracoronary ECG will be performed and if found it will be treated pharmacologically

Full detailed description

The study will include patients with coronary lesions and PCI. It will include patients with stable or unstable angina, without elevated hs-TnT. PCI will be performed and monitoring of intracoronary ST elevation. Any dissection or acute vessel closure will be promptly treated with balloon or stenting. Although there could be good angiographic result sometimes ischemia could be detected in the treated region by means of intracoronary ECG ST elevation above 1mm. This study aims to tackle this issue with randomization of the patients into three possible treatments - intracoronary adenosine, IIb/IIIa inhibitors or nitroglycerine alone - intracoronary ST segment will be searched for reverse or residual ischemia after the pharmacologic bolus. The intracoronary electrocardiography (i.c. ECG) is a very sensitive method for ischemia detection. The i.c. ECG reacts earlier on ischemia; the changes are much more prominent and easy to register. The wire tip could be positioned directly in different regions and thus to "map" regional ischemia. In most of the studies and from our own observations became evident that when surface ECG do not react the i.c. ECG demonstrates significant changes in ST-segment and QRS complex. Moreover, the registration of i.c. ECG is very cheap and needs only an adapter connecting coronary wire end and ECG. An i.c. ECG also can differentiate residual ischemic changes in distal main vessel and side branch as sources of prolonged ischemia, respectively - source of periprocedural myonecrosis. Once good angiographic result is obtained after stenting there could be different reasons for ischemia in the treated region - microembolic debris or coronary microvascular spasm.

Interventions

Treatment arms and agents.

DRUG

Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)

intracoronary drugs

Timeline

From registration to results.

  1. First posted

    Dec 26, 2017

  2. Study start

    Jan 3, 2018

  3. Primary completion

    Dec 5, 2019

  4. Study completion

    Dec 5, 2019

  5. Results posted

    Not reported

  6. Registry updated

    Dec 26, 2017

Outcomes

What the study measures.

Primary outcomes

Intracoronary ischemia change after intracoronary drug bolus

Time frame · 12 months

Look for ischemia change after intracoronary drugs

Secondary outcomes

Target lesion revascularization

Time frame · 12 months

Any revascularization at the territory of previously implanted stent.

Number of patients not alive

Time frame · 12 months

death

Myocardial infarction

Time frame · 12 months

MI after discharge

New onset angina or heart failure symptoms

Time frame · 12 months

New onset angina symptoms of at least CCS class II; New onset dyspnea at exertion or at rest

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
100 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Subject at least 18 years of age. * Target lesion(s) located in a native coronary artery with diameter of ≥ 2.5 mm and ≤ 4.5 mm. If there is side branch lesion(s) located in a native coronary artery with diameter of ≥ 2.0 mm. * Target lesion(s) amenable for PCI with balloon angioplasty of the side branch. Exclusion Criteria: * Subjects with significant ST-T change (≥ 1mm). * Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment). * Subjects who refuse to give informed consent. * Subjects with the following angiographic characteristics: left main coronary artery stenosis, total occlusion target lesion, lesion of interest located at infarct-related artery. * Subjects with LVEF \< 30%. * Subjects with moderate or severe degree valvular heart disease or primary cardiomyopathy. * LBBB, RBBB, atrial fibrillation/flutter with no identifiable isoelectric line.

Study locations

1 registered sites.

Bulgaria. Showing up to 24 locations stored in the fast local snapshot.

Alexandrovska University Hospital

Sofia, Bulgaria

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Eptifibatide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.